Custom Search

Gemfibrozil News

Early gemfibrozil therapy beneficial in dyslipidemia

Patients with dyslipidemia benefit from early gemfibrozil treatment, particularly if they have coronary heart disease (CHD) risk factors related to the metabolic syndrome, long-term follow-up data from a Finnish study indicate.

Lipoprotein particles explain fibrate benefit in VA-HIT

Lipoprotein particle subclasses predict coronary events and are improved by gemfibrozil therapy, a new analysis of the VA-HIT study has found.

HDL Becoming Important Piece of CHD Puzzle

For many years, clinical guidelines on the treatment of dyslipidemias have focused on reducing low-density lipoprotein (LDL) cholesterol. However, emerging science, when combined with earlier epidemiological research, is...

Displaying results 6 to 8 out of 8

< Previous



Use of this site is subject to the following terms of use